CFTR and cystic fibrosis: Even the combination of VX-770 and VX-809 led only to modest improvement of the respiratory function in phase II [36] and III [37] clinical trials in ΔF508/ΔF508 CF patients, suggesting an urgent need of boosting the activity of CFTR modulators.